What is Indaptus Therapeutics?
Indaptus Therapeutics, Inc. is a New York City-based biotechnology firm operating at the clinical stage of development. The company is dedicated to pioneering novel immunotherapies aimed at combating cancer and infectious diseases. Its core strategy involves harnessing the body's intrinsic immune defenses, employing engineered, non-pathogenic gram-negative bacteria to stimulate a broad spectrum of immune responses. This unique platform technology positions Indaptus Therapeutics at the forefront of next-generation therapeutic development.
How much funding has Indaptus Therapeutics raised?
Indaptus Therapeutics has raised a total of $2.3M across 1 funding round:
Debt
$2.3M
Debt (2025): $2.3M with participation from Paulson Investment Company
Key Investors in Indaptus Therapeutics
Paulson Investment Company
Paulson Investment Company is an investment banking firm specializing in the small to mid-cap markets, known for leveraging capital markets capabilities to assist clients in achieving strategic and financial objectives through long-term relationships and enduring values.
What's next for Indaptus Therapeutics?
The recent major strategic investment signals a critical growth phase for Indaptus Therapeutics. This influx of capital is expected to accelerate the company's clinical trial progression, potentially enabling further pipeline expansion and the advancement of its lead candidates toward commercialization. The strategic nature of this financing suggests strong confidence from investors in Indaptus's long-term vision and its capacity to deliver impactful treatments in oncology and infectious disease markets. Future developments will likely focus on key clinical milestones and strategic partnerships to maximize the therapeutic and commercial potential of its innovative platform.
See full Indaptus Therapeutics company page
